With a trusted contract manufacturing partner, pharmaceutical companies can ensure that their innovative therapies can come to market efficiently without compromising the quality and the safety of the drug and its delivery system.
Maximized uptime, minimized changeover time, and efficient OEE are key factors that have influenced the acceptance of aseptic blow-fill-seal in the packaging of pharmaceutical liquids.
BFS technology has been gaining increasing worldwide acceptance in the parenteral drug marketplace, replacing traditional glass vial processing in a growing number of applications.
Aseptic blow-fill-seal systems for packaging pharmaceutical liquids incorporate materials and process that provide critical advantages for sustainable initiatives.
A customer enlisted Catalent to support their child-resistant blister packaging requirements for a global Phase III study. A flexible design was created with an integrated blister card that could also support larger study requirements of 1.9 million monthly dosing cards. Through customized commercial blistering equipment a solution was provided that would accommodate the customer’s growing demands for clinical supplies.
Understand the strategies which can be employed at the different stages of development when choosing parenteral dosage forms.
This method can be used to identify potential points of weakness in a film or seal during the manufacturing process by simulating circumstances whereby the material may burst during packaging and transport.